Analysis of immune subtypes based on immunogenomic profiling identifies prognostic signature for cutaneous melanoma
- PMID: 33168410
- DOI: 10.1016/j.intimp.2020.107162
Analysis of immune subtypes based on immunogenomic profiling identifies prognostic signature for cutaneous melanoma
Abstract
Skin cutaneous melanoma (SKCM) is the most invasive form of skin cancer with poor prognosis. Growing evidence has demonstrated that tumor immune microenvironment plays a key contributing role in tumorigenesis and predicting clinical outcomes. The aim of this study was to recognize immune classification and a reliable prognostic signature for patients with SKCM. By using single-sample gene set enrichment (ssGSEA) and hierarchical clustering analyses, we evaluated the immune infiltration landscape of SKCM afflicted patients from The Cancer Genome Atlas (TCGA) dataset and named two SKCM subtypes: Immunity-high and Immunity-low. The Immunity-high subgroup was characterized by up-regulation of immune response and favorable survival probability. Seven candidate small molecule drugs which potentially reverse SKCM immune status were identified by using Connectivity map (CMap) database. A prognostic five-immune-associated gene (IAG) signature consisting IFITM1, TNFSF13B, APOBEC3G, CCL8 and KLRK1 with high predictive value was established using the LASSO Cox regression analysis in training set, and validated in testing set as well as Gene Expression Omnibus (GEO) external validation cohort (P < 0.05). Lower tumor purity and active immune-related signaling pathways were obviously presented in low-risk group. Furthermore, a novel composite nomogram based upon the five-IAG signature and other clinical parameters was built with excellent calibration curves. Collectively, comprehensively characterizing the SKCM subtypes based upon immune microenvironment landscape and development of a survival-related IAG signature may provide a promising avenue for improving individualized treatment design and prognosis prediction for patients with SKCM.
Keywords: Immune phenotype; Prognostic model; Skin cutaneous melanoma; Tumor immune microenvironment.
Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.
Similar articles
-
Development and validation of an immune gene set-based prognostic signature in cutaneous melanoma.Future Oncol. 2021 Nov;17(31):4115-4129. doi: 10.2217/fon-2021-0104. Epub 2021 Jul 22. Future Oncol. 2021. PMID: 34291650
-
Development of an IFNγ response-related signature for predicting the survival of cutaneous melanoma.Cancer Med. 2020 Nov;9(21):8186-8201. doi: 10.1002/cam4.3438. Epub 2020 Sep 9. Cancer Med. 2020. PMID: 32902917 Free PMC article.
-
Based on scRNA-seq and bulk RNA-seq to establish tumor immune microenvironment-associated signature of skin melanoma and predict immunotherapy response.Arch Dermatol Res. 2024 May 25;316(6):262. doi: 10.1007/s00403-024-03080-3. Arch Dermatol Res. 2024. PMID: 38795156
-
Targeting tumour metabolism in melanoma to enhance response to immune checkpoint inhibition: A balancing act.Cancer Treat Rev. 2024 Sep;129:102802. doi: 10.1016/j.ctrv.2024.102802. Epub 2024 Jul 11. Cancer Treat Rev. 2024. PMID: 39029155 Review.
-
Advances in adjuvant therapy: potential for prognostic and predictive biomarkers.Methods Mol Biol. 2014;1102:45-69. doi: 10.1007/978-1-62703-727-3_4. Methods Mol Biol. 2014. PMID: 24258973 Free PMC article. Review.
Cited by
-
Natural killer (NK) cells-related gene signature reveals the immune environment heterogeneity in hepatocellular carcinoma based on single cell analysis.Discov Oncol. 2024 Sep 4;15(1):406. doi: 10.1007/s12672-024-01287-4. Discov Oncol. 2024. PMID: 39231877 Free PMC article.
-
Prognostic signature and immune efficacy of m1 A-, m5 C- and m6 A-related regulators in cutaneous melanoma.J Cell Mol Med. 2021 Sep;25(17):8405-8418. doi: 10.1111/jcmm.16800. Epub 2021 Jul 21. J Cell Mol Med. 2021. PMID: 34288419 Free PMC article.
-
Identification and validation of an epithelial mesenchymal transition-related gene pairs signature for prediction of overall survival in patients with skin cutaneous melanoma.PeerJ. 2022 Jan 21;10:e12646. doi: 10.7717/peerj.12646. eCollection 2022. PeerJ. 2022. PMID: 35116193 Free PMC article.
-
Comparative Analysis of the Effect of the BRAF Inhibitor Dabrafenib in 2D and 3D Cell Culture Models of Human Metastatic Melanoma Cells.In Vivo. 2024 Jul-Aug;38(4):1579-1593. doi: 10.21873/invivo.13608. In Vivo. 2024. PMID: 38936891 Free PMC article.
-
The Multi-Omics Landscape and Clinical Relevance of the Immunological Signature of Phagocytosis Regulators: Implications for Risk Classification and Frontline Therapies in Skin Cutaneous Melanoma.Cancers (Basel). 2022 Jul 22;14(15):3582. doi: 10.3390/cancers14153582. Cancers (Basel). 2022. PMID: 35892841 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical